Andere Sprachen Innovent Biologics, Inc.

Aktien

A2N7N8

KYG4818G1010

1801

Markt geschlossen - Hong Kong S.E. Andere Börsenplätze 10:08:28 24.05.2024			% 5 Tage	% 1. Jan.
35,9 ^HKD	-2,97 %		-10,36 %	-16,02 %

21.05.	Chinesische Aufsichtsbehörde akzeptiert Innovent Biologics' Antrag auf ein neues Medikament gegen Schilddrüsenerkrankungen	MT
07.05.	Innovent erhält NMPA Breakthrough Therapy Designation für IBI343 (Anti-Claudin18.2 ADC) als Monotherapie für fortgeschrittenen Magenkrebs	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Innovent Announces the New Drug Application of IBI311 has been accepted by the NMPA of China for Thyroid Eye Disease	22.05.
Chinese Regulator Accepts Innovent Biologics' New Drug Application for Thyroid Eye Disease Drug	21.05.
Innovent Biologics Announces Oral Presentations at ESMO Plenary and ESMO GI Congress on Clinical Data of IBI363 and IBI343	20.05.
Head-to-head Superiority to High-dose Dulaglutide, Innovent's First Phase 3 Clinical Trial of Mazdutide in Chinese Patients with Type 2 Diabetes Met Study Endpoints	10.05.
Innovent Receives NMPA Breakthrough Therapy Designation for IBI343(Anti-Claudin18.2 ADC) as Monotherapy for Advanced Gastric Cancer	07.05.
Innovent Announces the Appointment of Dr. Samuel Zhang as Global Chief Business Officer	01.05.
Innovent Biologics, Inc. Reports Revenue Results for the First Quarter of 2024	30.04.
Innovent Biologics, Inc. Appoints Samuel Zhang as Global Chief Business Officer	30.04.
Innovent Announces the Appointment of Dr. Nageatte Ibrahim as the Oncology Chief Medical Officer	17.04.
Innovent Appoints Dr. Nageatte Ibrahim as the Oncology Chief Medical Officer	17.04.
Innovent and HUTCHMED Jointly Announce NDA Acceptance in China for Sintilimab Combination with Fruquintinib for the Treatment of Advanced Endometrial Cancer with Priority Review Status	03.04.
Hutchmed endometrial cancer treatment application accepted for review	02.04.
Hutchmed, Innovent Biologics Say Chinese Regulator Accepts Application for Endometrial Cancer Drug Combination	02.04.
HSBC in special payout on Canada sale; Astra FDA win	02.04.
Innovent Biologics New Cancer Drug Gets NDA from Chinese Authority	02.04.
HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Endometrial Cancer with Priority Review Status	02.04.
Innovent Biologics, Inc. Announces the National Medical Products Administration Accepts the New Drug Application	02.04.
Innovent Biologics' Loss Narrows in 2023 as Revenue Grows	21.03.
Innovent Biologics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	20.03.
Innovent Biologics, Inc. Releases the Results of Two Clinical Studies of Ibi311 (An Anti-IGF-1R Monoclonal Antibody) in Oral Presentations At the Asia-Pacific Academy of Ophthalmology Congress and International Congress of Endocrinology 2024	07.03.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Innovent Biologics, Inc.

Aktien

A2N7N8

KYG4818G1010

1801

Andere Sprachen

Filter